In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

Elevating Medication Adherence and Clinical Outcomes with Connected Drug Delivery
Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Aptar Pharma Injectable Expansion – Capacity, Capabilities and Partnership
Publications, Pharmaceutical, Market Insights, Product Solutions

Injectable Primary Packaging support compliance with Annex 1 Revision
Publications, Pharmaceutical, Market Insights, Product Solutions, Brand Differentiation

Ensuring Container Integrity at Various Temperatures
Webinars, Pharmaceutical, Market Insights, Product Solutions